Previous 10 | Next 10 |
Company Announces Retirement of Board of Director Veteran Dennis Langer Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the appointment of Patrick Gray to the Dicerna boar...
Dicerna™ Pharmaceuticals, Inc. (Nasdaq:DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, wi...
In terms of controlling what they can control, I believe Alnylam Pharmaceuticals ( ALNY ) management is doing a good job. While there has certainly been criticism of the high cash burn and the large sums that the company spends on R&D, I believe funding a robust Phase III development pro...
Dicerna Pharmaceuticals, Inc. (DRNA) Q2 2019 Earnings Conference Call August 8, 2019 4:30 PM ET Company Participants Lauren Stival – Investor Relations Doug Fambrough – President and Chief Executive Officer Jack Green – Chief Financial Officer Ralf Rosskamp...
Dicerna Pharmaceuticals (NASDAQ: DRNA ): Q2 GAAP EPS of -$0.35 misses by $0.04 . More news on: Dicerna Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
— Strengthened Management with Senior Hires Across Medical Affairs, Commercial, Regulatory, and Patient Advocacy and Patient Services — — Initiated dosing in PHYOX™3 Roll-over Extension Study for the Treatment of Primary Hyperoxaluria (PH) — ...
Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its second quarter 2019 financial results af...
The FDA has designated Dicerna Pharmaceuticals' ( DRNA +0.5% ) RNAi candidate DCR-PHXC a Breakthrough Therapy for the treatment of a rare inherited kidney disorder called primary hyperoxaluria type 1 (PH1). More news on: Dicerna Pharmaceuticals, Inc., Healthcare stocks news, ...
—Designation Follows Recently Reported PHYOX™1 Phase 1 Data Showing Positive Clinical Responses to DCR-PHXC— —FDA Recognizes Primary Hyperoxaluria Types 2 and 3 (PH2 and PH3) as Meeting Criteria for a Serious or Life-Threatening Disease or Condition— ...
Dicerna Pharmaceuticals ( DRNA ) is a clinical-stage company with RNAi-based therapies in development for multiple diseases. Its most advanced therapy is DCR-PHX for Primary Hyperoxaluria, which is currently in a Phase 1 trial. To be approved for commercial use by the FDA it would need to pass...
News, Short Squeeze, Breakout and More Instantly...
Dicerna Pharmaceuticals Inc. Company Name:
DRNA Stock Symbol:
NASDAQ Market:
Dicerna Pharmaceuticals Inc. Website:
Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. (Dicerna; Nasdaq: DRNA), announced on 18 November 2021, has been completed. Following the expiration of Novo Nordisk’s cash tender offer for Dicerna, Novo Nordisk has today acquired all outstan...
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with Novo Nordisk’s cash tender offer for Dicerna expired at 11:59 p.m., Easter...
Direxion Launches mRNA ETF (MSGR) MSGR Offers Exposure to Rapidly Evolving mRNA Sector PR Newswire NEW YORK , Dec. 9, 2021 /PRNewswire/ -- Direxion announced today the launch of the Direxion mRNA ETF (Ticker: MSGR) . MSGR invests in companies ...